Erkrath, Germany (ots)
- The transatlantic biopharmaceutical
company CARDION AG, with operating entities in Erkrath and Boston
(USA), expanded its executive board effective January 1, 2002.
In addition to CARDION's Chief Executive Officer Dr. Michael Ruhl,
Mr. Niels Ackermann and Dr. Manfred Rüdiger have been appointed to
become members of CARDION's executive board:
* Niels Ackermann, Chief Financial Officer, previously worked in
the investment banking division of Goldman Sachs where he gained
extensive experience in the mergers & acquisitions business as well
as the preparation of initial public offerings of German companies at
the Neuer Markt and NASDAQ. He joined CARDION in September 2001 and
took over the position of CFO at the same time.
* Dr. Manfred Ruediger, Chief Scientific Officer, joined CARDION
in 1998. Since then he has played a significant role in strengthening
the company's therapeutic focus on inflammatory and cardiovascular
disorders. Following his appointment Dr. Ruediger will hold
responsibility for the research & development process from drug
discovery to phase IIa of clinical development.
CARDION AG is a uniquely positioned biopharmaceutical company that
concentrates on the development of innovative, potentially curative
therapeutics for the treatment of inflammatory and cardiovascular
diseases. CARDION, founded in 1996, is focusing on highly attractive,
rapidly growing areas: a novel immunotherapeutic protein for the
treatment of Rheumatoid Arthritis and other Inflammatory diseases,
cardiovascular disorders and a stem cell platform for the creation of
regenerative medicine products (with initial focus on the treatment
of Type I diabetes).
For further details please visit our homepage www.cardion.de
ots Originaltext: CARDION AG